DK0975347T3 - Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister - Google Patents

Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister

Info

Publication number
DK0975347T3
DK0975347T3 DK98913584T DK98913584T DK0975347T3 DK 0975347 T3 DK0975347 T3 DK 0975347T3 DK 98913584 T DK98913584 T DK 98913584T DK 98913584 T DK98913584 T DK 98913584T DK 0975347 T3 DK0975347 T3 DK 0975347T3
Authority
DK
Denmark
Prior art keywords
agonists
adenylate cyclase
guanyl
cyclist
synergistic combination
Prior art date
Application number
DK98913584T
Other languages
English (en)
Inventor
Rolf Beume
Dieter Flockerzi
Christian Schudt
Klaus-Dieter Beller
Friedrich Grimminger
Norbert Suttorp
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Application granted granted Critical
Publication of DK0975347T3 publication Critical patent/DK0975347T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98913584T 1997-02-28 1998-02-24 Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister DK0975347T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19708049 1997-02-28
PCT/EP1998/001047 WO1998037894A1 (de) 1997-02-28 1998-02-24 Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten

Publications (1)

Publication Number Publication Date
DK0975347T3 true DK0975347T3 (da) 2008-06-16

Family

ID=7821764

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98913584T DK0975347T3 (da) 1997-02-28 1998-02-24 Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister

Country Status (12)

Country Link
US (1) US6333354B1 (da)
EP (1) EP0975347B1 (da)
JP (2) JP2001513097A (da)
AT (1) ATE386531T1 (da)
AU (1) AU6823098A (da)
CY (1) CY2607B2 (da)
DE (1) DE59814173D1 (da)
DK (1) DK0975347T3 (da)
ES (1) ES2302350T3 (da)
PT (1) PT975347E (da)
SI (1) SI0975347T1 (da)
WO (1) WO1998037894A1 (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE273996T1 (de) * 1997-09-12 2004-09-15 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
CZ293735B6 (cs) * 1998-08-26 2004-07-14 Smithkline Beecham Corporation Farmaceutický prostředek pro léčbu plicní nemoci
IL137429A0 (en) * 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
AU779991B2 (en) * 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
CA2715683A1 (en) * 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
CZ20023997A3 (cs) 2000-06-05 2003-05-14 Altana Pharma Ag Pyridazinonové deriváty
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
DE10061137B4 (de) * 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
JP2005509621A (ja) * 2001-10-17 2005-04-14 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン ギャップ結合ならびにedhf
EP1461022A2 (en) * 2001-12-17 2004-09-29 ALTANA Pharma AG Use of selective pde5 inhibitors for treating partial and global respiratory failure
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
WO2003087333A2 (en) * 2002-04-12 2003-10-23 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2003237078C1 (en) * 2002-04-12 2009-10-08 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
MXPA04011335A (es) * 2002-05-16 2005-07-01 Pharmacia Corp Metodos para el tratamiento de enfermedades y afecciones respiratorias con un inhibidor selectivo de inos y un inhibidor de pde y composiciones para esto.
KR20050004155A (ko) * 2002-05-16 2005-01-12 파마시아 코포레이션 선택적 유도성 산화질소 신타아제 억제제를 이용한 호흡기질병 및 질환의 치료 방법
BR0314364A (pt) * 2002-09-16 2005-07-19 Alcon Mfg Ltd Uso de inibidores de pde iv para tratar angiogênese
BR0316451A (pt) * 2002-11-27 2005-10-11 Altana Pharma Ag Combinação sinergìstica compreendendo roflumilast e formoterol
KR20050094810A (ko) * 2002-11-27 2005-09-28 알타나 파마 아게 로플루미래스트와 r,r-포르모테롤을 포함하는 상승작용성조합물
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
ATE477268T1 (de) 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
BRPI0409492A (pt) * 2003-04-18 2006-05-02 Pharmacia & Up John Company Ll terapias de combinação
BRPI0610498A2 (pt) 2005-04-19 2010-06-22 Nycomed Gmbh uso de roflumilast,composição farmacêutica, produto de combinação e kit para o tratamento de hipertensão pulmonar
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MX2010010334A (es) * 2008-03-24 2010-10-08 Celgene Corp Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
WO2010019450A2 (en) * 2008-08-09 2010-02-18 Nyles Bauer Synergizing active compounds for treating inflammation and other conditions
KR20170091783A (ko) 2008-12-31 2017-08-09 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 nhe-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2400970A4 (en) * 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE-1-HEMMER FOR EYE DRESSING
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SMT201900386T1 (it) 2013-04-12 2019-09-09 Ardelyx Inc Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
CN106333953A (zh) * 2015-07-08 2017-01-18 珠海津之敦医药科技有限公司 尤克那非新用途
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス, インコーポレイテッド Nhe媒介性アンチポートの阻害薬
AU2018205400C1 (en) 2017-01-09 2026-01-15 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
EP3937969A1 (en) 2019-03-14 2022-01-19 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3405181A1 (de) * 1984-02-10 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPH01153634A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 吸入剤
IT1239281B (it) * 1989-10-27 1993-10-19 Indena Spa Composizioni per la riduzione dei depositi di grasso superfluo a base di principi attivi di origine vegetale ad attivita' agonista dell'adenilato ciclasi o/e ad attivita' antifosfodiesterasica
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
US6013827A (en) * 1994-03-11 2000-01-11 Smithkline Beecham Corporation Compounds
US5602110A (en) 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis

Also Published As

Publication number Publication date
WO1998037894A1 (de) 1998-09-03
SI0975347T1 (sl) 2008-08-31
ATE386531T1 (de) 2008-03-15
CY2607B2 (en) 2010-04-28
JP2001513097A (ja) 2001-08-28
AU6823098A (en) 1998-09-18
EP0975347B1 (de) 2008-02-20
JP2009073853A (ja) 2009-04-09
ES2302350T3 (es) 2008-07-01
DE59814173D1 (de) 2008-04-03
PT975347E (pt) 2008-05-23
EP0975347A1 (de) 2000-02-02
US6333354B1 (en) 2001-12-25

Similar Documents

Publication Publication Date Title
PT975347E (pt) Combinação sinérgica de inibidores da pde e agonistas da adenilato ciclase ou agonistas da guanil ciclise
NO20083175L (no) Synergistisk analgetisk kombinasjon av opioid analgetikum og cyklooksigenase-2 inhibitor
ATE332129T1 (de) Behandlung der akne mit lipoxygenase inhibitoren
KR870005637A (ko) 약물 데포
ZA949539B (en) Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors.
FR2625906B1 (fr) Surf a neige
EA200100688A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОБИЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
EA199800633A1 (ru) Новые замещенные производные имидазола
DK0957914T3 (da) Formulering af 5-HT-agonister
FI962494L (fi) 5-(2-imidatsolinyyliamino)bentsimidatsolijohdannaisia, niiden valmistus ja niiden käyttö alpha-2-adrenoseptoriagonisteina
TR199801419T2 (xx) S�lfone amino asit t�revleri ve ayn� i�erikte metaloproteinez �nleyicileri.
DE69931908D1 (de) Steigerung der antikörper-zytokin-fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
YU81991A (sh) Sinergističke terapeutske kompozicije i postupci
SE9704870D0 (sv) New pharmaceutical formulation I
EA200100687A1 (ru) Комбинированная химиотерапия
ATE374917T1 (de) Zerlegbares gewehr
CO4900022A1 (es) Composicion topica y metodo para incrementar la sintesis de la barrera del lipido la barrera de lipido utilizando dicha composicion
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
DK0520032T3 (da) Anvendelse af spiperon som immunundertrykkende og antiinflammatorisk middel
Rubanyi et al. Effect of cilazapril and indomethacin on endothelial dysfunction in the aortas of spontaneously hypertensive rats
ATE186641T1 (de) Cytokinhemmer
IT1264630B1 (it) Protezione antigrippaggio perfezionata per giunti particolarmente adatta nel campo petrolifero
SE8206967D0 (sv) Vantskruv
NO20003758L (no) Trekonserveringsmidler
FI944727L (fi) Indolijohdannaisia 5-HT1:n kaltaisina agonisteina